The latest from the industry: FDA and EMA approvals, pivotal clinical trials, Eli Lilly and Novo Nordisk moves, mergers and acquisitions, and scientific publications shaping the global peptide market.
VIEW CATALOG
While semaglutide dominates clinical practice and tirzepatide owns the headlines, Eli Lilly is writing the next chapter with retatrutide — a triple GLP-1/GIP/glucagon agonist that already crossed -22 % body-weight loss in phase II. Review of the regulatory status in Spain, expected EMA timeline, current grey market and how it differs clinically from its predecessors.
Read full story
The agency confirmed the national shortage was resolved and gave 503A compounders until February 19, 2025 (semaglutide: May 22) to stop production. Eli Lilly and Novo Nordisk push the legal angle; telehealth and 503B outsourcers scramble to pivot.
Read full story
The much-anticipated Wegovy successor delivered 22.7% average weight loss at 68 weeks, below the 25% management had guided to. The stock erased $100 billion of market cap in a single day and reopened the GLP-1 war with Eli Lilly.
Read full storyAfter the eye-popping 24.2% phase 2 result, Eli Lilly has activated five pivotal trials covering obesity, type 2 diabetes, fatty liver and sleep apnea. FDA approval is projected for late 2026, potentially making retatrutide the best-selling GLP-1 of all time.
Read full storyWith no visible weight-loss plateau at trial end, MariTide combines an anti-GIP antibody with a GLP-1 agonist, enabling a single monthly injection. Amgen moves straight to phase 3, opening a serious third front against Lilly and Novo.
Read full storyThe Swiss pharma closes its gap in the obesity market by acquiring Carmot, a California biotech in phase 2 with a weekly GLP-1/GIP (CT-388) and a daily oral GLP-1 (CT-996). The move pressures Pfizer and Sanofi, both without a serious asset in the category.
Read full storyThe SELECT study showed a 20% reduction in major adverse cardiovascular events. The new indication forces Medicare and many insurers to cover Wegovy on medical grounds — a 180-degree shift from its 'cosmetic' framing through 2023.
Read full storyThe NYSE-listed telehealth platform jumped from $600M to $1.5B in 2024 revenue riding the compounded GLP-1 boom. After the May 22 regulatory cutoff, its strategy turns to selling 'personalized compounds' — with Eli Lilly and Novo aiming directly at it.
Read full storyMetabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is the leading cause of liver transplant in the US. The SYNERGY-NASH trial showed tirzepatide 15 mg weekly resolves the disease in 62% of patients at 52 weeks — eclipsing the first MASH-specific drug approved in March 2024.
Read full storyThe oral Wegovy successor posted a 13.1% drop at 12 weeks vs 1.1% on placebo in its phase 1. Novo stock closed up 8%. It's the first clinical evidence that combining GLP-1 + amylin in a single oral peptide can match injection-level efficacy.
Read full story
The largest systematic analysis to date on semaglutide and tirzepatide — 175 clinical trials, 215,970 participants — shows statistically significant reductions in mortality (12%), stroke (10%) and dementia (12%), on top of the expected metabolic benefits.
Read full storyThe German pharma, partnered with Zealand Pharma, releases final phase 2 data with 18.7% weight loss at 46 weeks and activates SYNCHRONIZE, its 4-trial pivotal program. For the first time Europe has its own competitive injectable obesity asset.
Read full storyReview of AEMPS legal framework for non-medicinal synthetic reagents, what to demand from a European supplier (HPLC ≥99%, external CoA, batch traceability), how customs handle these shipments, and why Spain has one of the smoothest intra-EU flows.
Read full storyTechnical review of pentadecapeptide BPC-157: origin (gastric extract), sequence GEPPPGKPADDAGLV, molecular weight 1,419 Da, mechanisms described in preclinical models (angiogenesis, nitric oxide, tendon recovery) and regulatory status in Spain as a research reagent.
Read full storyThe three molecules defining the global GLP-1 market compared by receptor targets, body-weight efficacy (-15% vs -22% vs -24%), HbA1c reduction, adverse-event profile, approved indications, Spain availability (CIMA) and key structural differences.
Read full storyThree years into the GLP-1 boom, the Spanish market still faces intermittent stock-outs, off-label prescription restrictions, and a private market polarized between authorized medicines and research reagents. Full February 2026 status review.
Read full storyComplete guide on peptide reagent logistics into Spain: what AEAT requires at customs, how cold chain is maintained in transit, intra-EU vs extra-EU lead times and costs, applicable TARIC code and how VAT is invoiced in B2B/B2C shipments.
Read full storyPublished articles may take up to 60 minutes to appear here.
Explore our research-grade peptide catalog with HPLC-certified ≥99% purity and 24-48h shipping across Europe.
View catalog